ICVTS Click here to go to Siemens website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Interact CardioVasc Thorac Surg 2007;6:661-664. doi:10.1510/icvts.2007.163386
© 2007 European Association of Cardio-Thoracic Surgery
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Shahzad G. Raja
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raja, S. G.
Right arrow Articles by Nagarajan, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raja, S. G.
Right arrow Articles by Nagarajan, K.
Related Collections
Right arrow Esophagus - cancer

Best evidence topic - Esophagus

Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer?

Shahzad G. Rajaa,*, Kareem Salhiyyahb and Kumaresan Nagarajana

a Department of Cardiothoracic Surgery (Level 9), Western Infirmary Glasgow, Dumbarton Road, Glasgow, G11 6NT, UK
b Department of Cardiac Surgery, Royal Hospital for Sick Children, Dalnair Street, Glasgow, G3 8SJ, UK

*Corresponding author. Fax: +441412111751.

E-mail address: drrajashahzad{at}hotmail.com (S.G. Raja).

A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was whether neoadjuvant chemotherapy improves survival in patients with resectable oesophageal cancer. Altogether 685 papers were identified using the below mentioned search. Nine represented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group, relevant outcomes and weaknesses were tabulated. We conclude that combining neoadjuvant chemotherapy with surgery for resectable thoracic oesophageal cancer has theoretical appeal and may offer a modest survival advantage compared to surgery alone. The most recent meta-analysis and the largest randomised trial of 804 patients demonstrated an absolute survival advantage of around 7–9% at two years which just reached statistical significance. Benefit was less clear for squamous cell carcinoma than adenocarcinoma and the second largest randomised trial did not demonstrate a significant benefit.

Key Words: Chemotherapy; Oesophageal carcinoma; Survival; Neoadjuvant chemotherapy

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 European Association for Cardio-thoracic Surgery